KALY Anticipates Explosive Growth In $22 Billion CBD Market From Hemp Legalization In $867 Billion Farm Bill
December 13 2018 - 10:30AM
InvestorsHub NewsWire
LY Anticipates Explosive
Growth In $22 Billion CBD Market From Hemp Farming Legalization In
$867 Billion Farm Bill
Dallas, TX -- December 13, 2018
-- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced that the company anticipates
explosive growth to result from the legalization of hemp farming
included in the 2018 Farm Bill. Yesterday, Congress passed
the $867 billion farm bill that includes the legalization of hemp
farming and President Trump is expected to soon sign the bill into
law. A report from the Brightfield Group projects that the
hemp-derived CBD market will rapidly expand from about $591
million this year to $22 billion by 2022.
Kali-Extracts recently acquired a patented cannabis extraction
process validated by research from major medical research
institutions. In anticipation of hemp farming being legalized
in the farm bill, Kali-Extracts has already been sought out and
engaged to begin producing custom hemp-derived CBD extracts.
Kali-Extracts recently announced a $300,000 contract weeks after
acquiring the patented cannabis extraction
process.
“Kali-Extracts has initiated a program to
construct mobile hemp-derived CBD extraction labs to be deployed to
hemp farms across America,” said incoming Kali-Extracts CEO Fred
Ferri. “Our extraction process has been proven in multiple research
initiatives. Some doctors working with our process have
indicated our extracts are superior to those of GW
Pharmaceuticals. I believe Kali-Extracts will be both the
biggest and the best producer of hemp derived CBD extracts in
America.”
For more information visit:
www.kali-extracts.com
Disclaimer/Safe
Harbor:
This news
release contains forward-looking statements within the meaning of
the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any
disease.
Contact:
Kali, Inc.
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024